Peptide Receptor Radionuclide Therapy Prolongs Survival in Neuroendocrine Neoplasms: A Single Centre Study in 1048 Patients over 10 Years

#1570

Introduction: Peptide receptor radionuclide therapy (PRRT) of somatostatin receptor (SSTR) expressing neuroendocrine neoplasms (NEN) has shown promising results about progression free survival (PFS) and overall survival (OS) in numerous phase II trials, and also in a recently published randomized controlled prospective phase III study (NETTER-1).

Aim(s): To assess the OS and PFS in NEN patients (pts) undergoing PRRT.

Materials and methods: Of the 2294 pts screened by Ga-68 SSTR PET/CT, 1048 pts received ≥1 cycle of Y-90 or Lu-177 based PRRT and were included in the intention to treat analysis. PFS determined by Ga-68 SSTR PET/CT was analyzed.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Kulkarni H

Authors: Baum R, Kulkarni H, Niepsch K, Kaemmerer D, Hommann M,

Keywords: PRRT, Survival, PET/CT,

To read the full abstract, please log into your ENETS Member account.